Empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, did not show significant benefit in reducing a first heart failure (HF) hospitalization or death from any cause in […]

A human apolipoprotein A1 (ApoA1) product, which is the key constituent of high-density lipoprotein (HDL) cholesterol and removes excess lipid from atherosclerotic plaques, did not bring […]

ATLANTA, GA — Despite promise for improving heart failure (HF) in pilot studies, an interarterial shunt (IAS) device did not meet the primary composite efficacy endpoint […]

Sodium-glucose transporter 2 (SGLT2) inhibitors are safe and well-tolerated in people with heart failure (HF) related to adult congenital heart disease (ACHD) and associated with reduced […]

Enrolment in a trial investigating a novel gene editing therapy in patients with heterozygous familial hypercholesterolemia (HeFH) has been paused after laboratory abnormalities, including a grade […]

Baseline lipoprotein a, or Lp(a), levels are strongly associated with major adverse cardiovascular events (MACE) in high-risk patients with elevated triglyceride levels receiving statin therapy, a […]

Genetic testing may be considered in patients with early-onset atrial fibrillation (AF), particularly those with a positive family history and lack of conventional clinical risk factors, […]

The US Food and Drug Administration (FDA) has approved Abbott’s TriClip Transcatheter Edge-to-Edge Repair (TEER) system to repair severe tricuspid regurgitation (TR), the company has announced.  […]

Half of patients aged 40 years or older in Canada have dyslipidemia, and prevalence among patients aged 65 years or older, men, and those with obesity […]